Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Biomedical Reports
Join Editorial Board Propose a Special Issue
Print ISSN: 2049-9434 Online ISSN: 2049-9442
Journal Cover
November-2015 Volume 3 Issue 6

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
November-2015 Volume 3 Issue 6

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article

Topiramate effects lipolysis in 3T3-L1 adipocytes

  • Authors:
    • Gabriela Poltronieri Campagnaro Martins
    • Camila Oliveira Souza
    • Scherolin de Oliveira Marques
    • Thais Fernandes Luciano
    • Bruno Luiz da Silva Pieri
    • José César Rosa
    • Adelino Sanchez Ramos da Silva
    • José Rodrigo Pauli
    • Dennys Esper Cintra
    • Eduardo Rochete Ropelle
    • Bruno Rodrigues
    • Fabio Santos de Lira
    • Claudio Teodoro de Souza
  • View Affiliations / Copyright

    Affiliations: Laboratory of Exercise Biochemistry and Physiology, Health Sciences Unit, University of Extremo Sul Catarinense, Criciúma, SC 88806‑000, Brazil, Immunometabolism Research Group, Institute of Biomedical Sciences, University of Sao Paulo, São Paulo, SP 05508‑900, Brazil, School of Physical Education and Sport of Ribeirão Preto, University of São Paulo (USP), Ribeirão Preto, SP 14040‑907, Brazil, School of Applied Sciences, University of Campinas (UNICAMP), Limeira, SP 13484‑350, Brazil, Laboratory of Human Movement, São Judas Tadeu University, São Paulo, SP 03166‑000, Brazil, Immunometabolism Research Group, Department of Physical Education, University Estadual Paulista (UNESP), Presidente Prudente, SP 19060‑900, Brazil
  • Pages: 827-830
    |
    Published online on: August 28, 2015
       https://doi.org/10.3892/br.2015.514
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

Studies have shown that topiramate (TPM)-induced weight loss can be dependent on the central nervous system (CNS). However, the direct action of TPM on adipose tissue has not been tested previously. Thus, the present study aimed to examine whether TPM modulates lipolysis in 3T3‑L1. The 3T3‑L1 cells were incubated in 50 µM TPM for 30 min. The β‑adrenergic stimulator, isoproterenol, was used as a positive control. The release of lactate dehydrogenase, non‑esterified fatty acid, glycerol and incorporation of 14C‑palmitate to lipid were analyzed. The phosphorylation of protein kinase A (PKA), hormone‑sensitive lipase (HSL), adipocyte triglyceride lipase (ATGL) and perilipin A, as well as the protein levels of comparative genetic identification 58 (CGI‑58) were assessed. The levels of glycerol and non‑esterified fatty acid increased markedly when the cells were treated with TPM. The TPM effects were similar to the isoproterenol positive control. Additionally, TPM reduced lipogenesis. These results were observed without any change in cell viability. Finally, the phosphorylation of PKA, HSL, ATGL and perilipin A, as well as the protein levels of CGI‑58 were increased compared to the control cells. These results were similar to those observed in the cells treated with isoproterenol. The present results show that TPM increased the phosphorylation of pivotal lipolytic enzymes, which induced lipolysis in 3T3‑L1 adipocytes, suggesting that this drug may act directly in the adipose tissue independent from its effect on the CNS.

Introduction

Obesity is associated with several chronic diseases. Environmental changes are not sufficient to control obesity; however, there is overwhelming evidence that certain pharmacological agents may act as therapeutic targets for obesity. One such agent is topiramate (TPM), initially used for epilepsy treatment and migraine prophylaxis. TPM is a glutamate α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid/kainate receptor agonist and enhances the inhibitory effects mediated by γ-aminobutyric acid (1). One of the side effects of TPM is weight loss, which makes this drug a possible option for obesity treatment. The central mechanisms suggested for TPM-induced weight loss include a reduction in energy efficiency, influence on the hypothalamus and alteration of neuropeptides (1). However, the direct action of TPM on adipose tissue, particularly on lipolysis, has not been observed.

Two essential enzymes for lipid hydrolysis are adipocyte triglyceride lipase (ATGL) and hormone-sensitive lipase (HSL). ATGL hydrolyzes triacylglycerols into a fatty acid and a diacylglycerol (2). To fully activate, ATGL must interact with its cofactor, comparative genetic identification 58 (CGI-58) (3). In adipocytes without lipolytic stimuli, CGI-58 is strongly bound to lipid droplets, interacting with perilipin A (2). However, perilipin A and CGI-58 dissociate when lipolytic activity is stimulated by the activation of β-adrenergic receptors, which causes an increase in the cyclic adenosine monophosphate and consequent activation of protein kinase A (PKA). This process releases CGI-58 to associate with ATGL. Perilipin A is a structural protein that coats lipid droplets and protects triglycerides (TAG) molecules from basal enzymatic hydrolysis (4). Additionally, in stimulated cells, perilipin A is phosphorylated and facilitates the HSL translocation from the fat vesicles surface with consequent access to its diacylglycerol substrate (5). Together, the phosphorylation of HSL and its translocation to the lipid droplets surface, coupled with the activation of ATGL by CGI-58, results in the hydrolysis of 90% of TAG.

TPM treatment has been shown to reduce adiposity in humans and rodents (6,7). TPM is assumed to act directly on lipolysis, however, this has not been explicitly described in vivo, once TPM acts on the central nervous system (CNS). Thus, in the present study, 3T3-L1 adipocytes were used and TPM was demonstrated to have a direct effect on lipolysis.

Materials and methods

Cell culture and measurement of lipolysis

3T3-L1 cells were obtained from the American Type Culture Collection and cultured at 37°C in 5% CO2 in Dulbecco's modified Eagle's medium supplemented with 25 mmol/l glucose, 1.0 mmol/l pyruvate, 4.02 mmol/l L-alanyl-glutamine and 10% fetal bovine serum (Gibco, New York, NY, USA). Cell differentiation began 24 h after confluency and occurred over 4 days in a medium containing 0.25 µM dexamethasone, 0.5 mmol/l 3-isobutyl-1-methylxanthine and 5 µg/ml insulin (Sigma, St. Louis, MO, USA). Following differentiation, the cells were cultured for 10 days in growth medium containing 5 µg/ml of insulin. Each parameter was evaluated using a 6-well aliquot from this culture. On day 10 after differentiation, the cells were incubated for 24 h in a medium containing 0.5% fetal bovine serum. Cells were treated with 10 µl of TPM (50 µM) or isoproterenol (20 µM) for 30 min. At the end of the incubation, the glycerol and non-esterified fatty acid (NEFA) contents (Wako Chemical, Richmond, Inc., VA, USA) of the incubation medium were used as an index of lipolysis and were measured using enzymatic-colorimetric kits. In addition, the release of lactate dehydrogenase (LDH) induced by plasma membrane disruption in culture medium was used as a cellular viability index.

Incorporation of [1-14C]-palmitate into lipids

Cells were incubated in Krebs/Ringer/phosphate buffer (pH 7.4), supplemented with 1% bovine serum albumin and 1 mmol/l palmitate, at 37°C under a CO2 (5%)/O2 (95%) gas mixture. Aliquots (450 µl) were transferred to polypropylene test tubes containing 5 µl of [1-14C]-palmitate, in the presence or absence of insulin (10 nmol/l), and in the presence or absence of TPM (50 µM). These samples were subsequently incubated for 1 h at 37°C in a water bath. Following incubation, the mixture was acidified with 0.2 ml H2SO4 (8 N) and incubated for an additional 30 min. At the end of the incubation, the reaction mixture was treated with 2.5 ml of Dole's reagent (isopropanol:n-heptane:H2SO4, 4:1:0.25, v/v/v) for lipid extraction.

Immunoblotting

The whole cell extracts were prepared by lysis of the cells in extraction buffer [1% Triton X-100, 100 mmol/l Tris (pH 7.4), containing 100 mmol/l sodium pyrophosphate, 100 mmol/l sodium fluoride, 10 mmol/l EDTA, 10 mmol/l sodium vanadate, 2 mmol/l phenylmethylsulphonyl fluoride and 0.1 mg of aprotinin/ml] at 4°C. The extracts were centrifuged at 9,000 × g at 4°C (5804R; Eppendorf AG, Hamburg, Germany) for 40 min to remove insoluble material, and the supernatants of these tissues were used for protein quantification, according to the Bradford method. Proteins were denatured by boiling in Laemmli sample buffer containing 100 mM dithiothreitol, run on SDS-PAGE and transferred to nitrocellulose membranes. Membranes were blocked, probed and blotted with primary antibodies. Antibodies used for immunoblotting were phospho HSLser660, phospho HSLser563, HSL total (Cell Signaling Technology, Beverly, MA, USA), and phospho PKAThr198, PKA total, CGI-58, perilipin A (Santa Cruz Biotechnology, Inc., Dallas, TX, USA), phospho ATGLSer406, ATGL total, β-actin (Abcam, Eugene, OR, USA), and phospho perilipin A (Vala Sciences, Inc., San Diego, CA, USA). Chemiluminescent detection was performed with horseradish peroxidase-conjugated secondary antibodies (Thermo Scientific, Rockford, IL, USA). Autoradiographs of membranes were obtained for visualization of protein bands. The results of the blots are presented as direct comparisons of the area of the apparent bands in autoradiographs and quantified by densitometry using the Scion Image software (Scion Image software; Scion Corp., Frederick, MD, USA).

Statistical analysis

Bars represent 6 different experiments. Differences between the groups were evaluated using one-way analysis of variance followed by the Bonferroni post hoc test. P<0.05 was considered to indicate a statistically significant difference. The software used for data analysis was the Statistical Package for the Social Sciences (SPSS) version 17.0 for Windows (SPSS, Inc., Chicago, IL, USA).

Results

Effects of TPM on lipolysis in 3T3-L1 adipocytes

To evaluate TPM-induced physiological alterations in lipolysis, the glycerol and NEFA contents were assayed in the incubation medium. The contents of glycerol and NEFA in isoproterenol-treated cells were higher compared with the control group. Similar results were observed for the isoproterenol group (Fig. 1A and B). To analyze lipogenesis, insulin-induced [1-14C]-palmitate incorporation into lipids was assayed. These results show that the use of TPM decreased palmitate incorporation into lipids compared to the control group regardless of insulin stimulus (Fig. 1C). To evaluate whether TPM exposure effects cellular viability, the cytosolic enzyme LDH release was quantified. The analyzed groups did not demonstrate significant differences, suggesting that TPM was not cytotoxic for the times and dosages used (Fig. 1D).

Figure 1.

Effects of topiramate on the lipolysis and lipogenesis in 3T3-L1 adipocytes. Adipocytes were incubated for 30 min at 37°C in the presence or absence of topiramate or isoproterenol. (A) Release of glycerol and (B) non-esterified fatty acid (NEFA) into culture medium was measured and expressed as mg/dl/µg of protein and nM/µl/µg of protein, respectively. Isoproterenol was the positive control. (C) The incorporation of [14C]-palmitate into lipids in the presence or absence of insulin (10 nmol/l) and presence or absence of topiramate (50 µM) was evaluated. The results are expressed as percentage of basal control. Cellular viability was evaluated by (D) monitoring lactate dehydrogenase (LDH) and expressed as mmol/l/dl/µg of protein. Phosphorylation of (E) protein kinase A (PKA), (F) hormone-sensitive lipaseSer660 (HSLSer660), (G) HSLSer563, (H) perilipin, (I) ATGLSer406 and (J) cofactor comparative genetic identification 58 (CGI-58) protein levels, respectively. The lower panel shows bands representative of PKA, HSL, perilipin, adipocyte triglyceride lipase (ATGL) and protein levels β-actin. Bars represent the mean ± standard error of the mean of 6 different experiments. *P<0.05, vs. control group. In Fig. 1C, *P<0.05 vs. control group without insulin (-) and #P<0.05 for topiramate vs. control group with insulin (+). CON, control; ISO, isoproterenol; TOP, topiramate.

Based on the current findings, we hypothesize that TPM treatment could increase the phosphorylation of the main lipolytic enzymes. Subsequently, the phosphorylation of PKAThr198, HSLSer660, HSLSer563, ATGLSer406 and perilipin A, as well as the protein levels of CGI-58, PKAThr198, HSLSer660, HSLSer563, ATGLSer406 and perilipin A were analyzed (Fig. 1E–J). TPM treatment led to a higher enzymatic phosphorylation compared to the control group. Therefore, this result may explain, at least in part, why the glycerol and NEFA levels were increased. Notably, the analyzed protein phosphorylation and the CGI-58 protein levels were similar for cells treated with TPM or isoproterenol (Fig. 1E–J).

Discussion

As increased lipolysis and decreased lipogenesis cause fat loss in obese individuals, the present study tested whether the use of TPM increases lipolysis in 3T3-L1 cells. The 3T3-L1 cells treated with TPM presented high phosphorylation of lipolytic enzymes and subsequent lipolysis, without alteration of cell viability. In addition, the data showed that TPM modulated lipogenesis. A previous 6-month randomized human study indicated that TPM led to marked weight loss compared to the placebo (8). Another recent study showed that co-treatment with phentermine and TPM also induced weight loss in obese patients (9). A study in which animals were fed with a high fat diet showed that the concurrent TPM use at 50 mg/kg led to body weight reduction and insulin sensitivity improvement (10). Caricilli et al (11) observed that TPM improved insulin and leptin sensitivity in the hypothalamus of obese mice, which can contribute to the reduction of food intake and adiposity. However, these in vivo studies did not exclude the TPM effects on CNS.

In the present study, TPM treatment increased the release of NEFA and glycerol in the culture medium. In addition, decreased [14C]-palmitate incorporation was observed in adipocytes exposed to TPM. One of the proposed mechanisms for lipogenesis reduction can be the carbonic anhydrase enzyme inhibition, which performs the first step of de novo lipogenesis. Although this enzyme was not analyzed in the present study, a previous study suggested that TPM can inhibit the cytosolic and mitochondrial levels of this enzyme, leading to weight loss (12).

Subsequent to observing that NEFA and glycerol levels were changed, five molecules that have a crucial role in the triacylglycerol hydrolysis were analyzed. TPM treatment increased the phosphorylation of PKA, HSL, ATGL and perilipin A, as well as the protein levels of CGI-58 compared to control cells. However, the TPM-induced phosphorylation degrees were similar to those using isoproterenol. The present data did not allow the proposition of the mechanism responsible by the increase of these molecules induced by TPM. Taken together, these results demonstrate that TPM treatment led to lipolysis independently of its action on the CNS. These data increase the understanding of the processes involved on the TPM-induced weight loss and suggest a direct action of this drug on the adipose tissue.

Acknowledgements

The present study was supported by grants from Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) and University of Extremo Sul Catarinense (UNESC).

Glossary

Abbreviations

Abbreviations:

ATGL

adipocyte triglyceride lipase

CGI-58

cofactor comparative genetic identification 58

CNS

central nervous system

HSL

hormone-sensitive lipase

LDH

lactate dehydrogenase

NEFA

non-esterified fatty acid

PKA

protein kinase A

TAG

triglycerides

TPM

topiramate

References

1 

Verrotti A, Scaparrotta A, Agostinelli S, Di Pillo S, Chiarelli F and Grosso S: Topiramate-induced weight loss: A review. Epilepsy Res. 95:189–199. 2011. View Article : Google Scholar : PubMed/NCBI

2 

Zechner R, Kienesberger PC, Haemmerle G, Zimmermann R and Lass A: Adipose triglyceride lipase and the lipolytic catabolism of cellular fat stores. J Lipid Res. 50:3–21. 2009. View Article : Google Scholar : PubMed/NCBI

3 

Lass A, Zimmermann R, Haemmerle G, Riederer M, Schoiswohl G, Schweiger M, Kienesberger P, Strauss JG, Gorkiewicz G and Zechner R: Adipose triglyceride lipase-mediated lipolysis of cellular fat stores is activated by CGI-58 and defective in Chanarin-Dorfman Syndrome. Cell Metab. 3:309–319. 2006. View Article : Google Scholar : PubMed/NCBI

4 

Sztalryd C, Xu G, Dorward H, Tansey JT, Contreras JA, Kimmel AR and Londos C: Perilipin A is essential for the translocation of hormone-sensitive lipase during lipolytic activation. J Cell Biol. 161:1093–1103. 2003. View Article : Google Scholar : PubMed/NCBI

5 

Brasaemle DL: Thematic review series: Adipocyte biology. The perilipin family of structural lipid droplet proteins: Stabilization of lipid droplets and control of lipolysis. J Lipid Res. 48:2547–2559. 2007. View Article : Google Scholar : PubMed/NCBI

6 

Ben Menachem, Axelsen M, Johanson EH, Stagge A and Smith U: Predictors of weight loss in adults with topiramate-treated epilepsy. Obes Res. 11:556–562. 2003. View Article : Google Scholar : PubMed/NCBI

7 

Picard F, Deshaies Y, Lalonde J, Samson P and Richard D: Topiramate reduces energy and fat gains in lean (Fa/?) and obese (fa/fa) Zucker rats. Obes Res. 8:656–663. 2000. View Article : Google Scholar : PubMed/NCBI

8 

Wilding J, Van Gaal L, Rissanen A, Vercruysse F and Fitchet M: OBES-002 Study Group: A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. Int J Obes Relat Metab Disord. 28:1399–1410. 2004. View Article : Google Scholar : PubMed/NCBI

9 

Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML and Day WW: Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): A randomised, placebo-controlled, phase 3 trial. Lancet. 377:1341–1352. 2011. View Article : Google Scholar : PubMed/NCBI

10 

Abo-Elmatty DM and Zaitone SA: Topiramate induces weight loss and improves insulin sensitivity in dietary obese rats: Comparison to sibutramine. Eur Rev Med Pharmacol Sci. 15:1187–1195. 2011.PubMed/NCBI

11 

Caricilli AM, Penteado E, de Abreu LL, Quaresma PG, Santos AC, Guadagnini D, Razolli D, Mittestainer FC, Carvalheira JB, Velloso LA, et al: Topiramate treatment improves hypothalamic insulin and leptin signaling and action and reduces obesity in mice. Endocrinology. 153:4401–4411. 2012. View Article : Google Scholar : PubMed/NCBI

12 

Supuran CT, Di Fiore A and De Simone G: Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs. 13:383–392. 2008. View Article : Google Scholar : PubMed/NCBI

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Martins GP, Souza CO, Marques Sd, Luciano TF, da Silva Pieri BL, Rosa JC, da Silva AS, Pauli JR, Cintra DE, Ropelle ER, Ropelle ER, et al: Topiramate effects lipolysis in 3T3-L1 adipocytes. Biomed Rep 3: 827-830, 2015.
APA
Martins, G.P., Souza, C.O., Marques, S.d., Luciano, T.F., da Silva Pieri, B.L., Rosa, J.C. ... de Souza, C.T. (2015). Topiramate effects lipolysis in 3T3-L1 adipocytes. Biomedical Reports, 3, 827-830. https://doi.org/10.3892/br.2015.514
MLA
Martins, G. P., Souza, C. O., Marques, S. d., Luciano, T. F., da Silva Pieri, B. L., Rosa, J. C., da Silva, A. S., Pauli, J. R., Cintra, D. E., Ropelle, E. R., Rodrigues, B., de Lira, F. S., de Souza, C. T."Topiramate effects lipolysis in 3T3-L1 adipocytes". Biomedical Reports 3.6 (2015): 827-830.
Chicago
Martins, G. P., Souza, C. O., Marques, S. d., Luciano, T. F., da Silva Pieri, B. L., Rosa, J. C., da Silva, A. S., Pauli, J. R., Cintra, D. E., Ropelle, E. R., Rodrigues, B., de Lira, F. S., de Souza, C. T."Topiramate effects lipolysis in 3T3-L1 adipocytes". Biomedical Reports 3, no. 6 (2015): 827-830. https://doi.org/10.3892/br.2015.514
Copy and paste a formatted citation
x
Spandidos Publications style
Martins GP, Souza CO, Marques Sd, Luciano TF, da Silva Pieri BL, Rosa JC, da Silva AS, Pauli JR, Cintra DE, Ropelle ER, Ropelle ER, et al: Topiramate effects lipolysis in 3T3-L1 adipocytes. Biomed Rep 3: 827-830, 2015.
APA
Martins, G.P., Souza, C.O., Marques, S.d., Luciano, T.F., da Silva Pieri, B.L., Rosa, J.C. ... de Souza, C.T. (2015). Topiramate effects lipolysis in 3T3-L1 adipocytes. Biomedical Reports, 3, 827-830. https://doi.org/10.3892/br.2015.514
MLA
Martins, G. P., Souza, C. O., Marques, S. d., Luciano, T. F., da Silva Pieri, B. L., Rosa, J. C., da Silva, A. S., Pauli, J. R., Cintra, D. E., Ropelle, E. R., Rodrigues, B., de Lira, F. S., de Souza, C. T."Topiramate effects lipolysis in 3T3-L1 adipocytes". Biomedical Reports 3.6 (2015): 827-830.
Chicago
Martins, G. P., Souza, C. O., Marques, S. d., Luciano, T. F., da Silva Pieri, B. L., Rosa, J. C., da Silva, A. S., Pauli, J. R., Cintra, D. E., Ropelle, E. R., Rodrigues, B., de Lira, F. S., de Souza, C. T."Topiramate effects lipolysis in 3T3-L1 adipocytes". Biomedical Reports 3, no. 6 (2015): 827-830. https://doi.org/10.3892/br.2015.514
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team